Introduction
Gene therapy offers the potential to contribute to the treatment of many human diseases, including inherited or acquired diseases. The hematopoietic progenitor cell (HPC) represents an attractive target cell for the introduction of corrective or protective genes into multiple lineages and can be readily isolated from the bone marrow, peripheral and umbilical cord blood, from which they can be transduced and eventually used to reconstitute the hematopoietic lineage of transplant recipients. Previous studies involving the transfection of CD34 + HPCs have mainly utilized murine leukemia virus (MLV)-derived retroviral vectors to transduce cells. Successful transfer and expression of various genes by these retroviral vectors into human bone marrow progenitors and long-term culture-initiating cells aimed at the eventual treatment of various diseases such as ADA deficiency, [1] [2] [3] [4] X-linked granulomatous disease, 5 alpha-l-iduronidase deficiency (Hurler syndrome), 6 Gaucher's disease [7] [8] [9] and AIDS 10, 11 Correspondence: GJ Nable, Howard have been reported. Other viral vectors based on the defective parvovirus, adeno-associated virus (AAV), [12] [13] [14] and an HIV-1 based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G 15 have also been used to produce stable gene transfer in hematopoietic cells.
A possible method for immune maintenance/reconstitution in the pediatric population is via the use of autologous cord blood (CB) stem/progenitor cells collected at birth from the umbilical cord of the mother. For example, in pediatric AIDS, therapeutic anti-HIV genes could be transduced into cord blood-derived CD34 + hematopoietic progenitor/stem cells and engrafted into the HIV-seropositive child. Establishment of these cells may confer protection to the various cells susceptible to HIV infection, especially cells of the myeloid and lymphoid lineages. Previous reports have begun to evaluate the expression, stability and efficacy of introducing HIV protective genes into hematopoietic stem/progenitor cells. MLV-derived retroviral vectors expressing Rev-responsive element (RRE) decoys, 11 hairpin ribozymes, 16, 17 and Rev M10 18 have been shown to confer a degree of resistance to HIV infection in macrophage-like cells derived from transduced progenitor/stem cells when challenged with diverse strains of HIV in vitro.
Given the extensive use of viral vectors for gene deliv-ery, questions remain about the possible emergence of replication-competent viruses and their subsequent oncogenic and pathogenic potential in immunosuppressed individuals. The development of efficient nonviral delivery systems would have potential advantages relative to viral gene delivery, including safety issues, ease of vector production, and the production and certification of viral producer cell lines and viral stocks. We now describe improved particle-mediated transfection of umbilical cord blood-derived CD34 + enriched cells and their subsequent differentiation potential in vitro.
Results
Optimization of particle-mediated gene transfer Particle-mediated gene transfer has been used successfully to transduce numerous primary animal cells, 19, 20 including human blood-derived T cells 21 and tumor cells. 22 To evaluate whether we could use the same procedure to transduce umbilical cord blood-derived CD34 + cells, we employed a CAT expression vector, CMV-CAT, as a reporter gene. The vector consists of a CAT gene whose expression is regulated by a CMV-derived enhancer/intron unit which has been shown previously to provide high levels of CAT expression in different transformed and primary cells. 23, 24 The vector also contains the selectable neomycin resistance gene (neo R ) under control of the SV40 enhancer which enables drug selection of cells with G-418 following transfection.
Before transfection of cord blood cells, optimization of gene transfer with the biolistics procedure was first performed. Human peripheral blood mononuclear cells (PBMC) were used for the initial optimization due to the their ease of isolation and availability compared with cord blood-derived CD34 + cells. From pilot experiments, it appeared that conditions that are optimal for PBMC transfection were similar to those for cord blood-derived cells (data not shown).
Various parameters related to the transfection procedure were optimized ( Figure 1 ). The size of the gold bead (Figure 1a) , distance between cells and beads ( Figure 1b) , and pressure used during the gene transfer procedure (Figure 1c ) had the greatest impact on gene transfer efficiency. These factors presumably affect transfection by altering bead penetration, overall cell viability, and the DNA binding capacity of the bead. Increasing the amount of DNA on the beads above 1 g reduced CAT activity, possibly due to charge effects influencing coating efficiency, and/or clumping of the DNA-coated beads. The optimal time of pre-stimulation before transfection was found between 48-72 h (data not shown). Comparable gene transfer efficiencies were also observed between distinct T cell subclasses, suggesting that there was no difference among different cell types to gene transfer using this physical method of DNA delivery (Figure 1d ). Not surprisingly, pre-activation of cells resulted in an increase in CAT activity (Figure 1e) , most likely the consequence of the increase in cell volume and overall metabolic activity of activated cells. Similar to previous results, 25 the CMV promoter was also found to be significantly more active in stimulating CAT expression than the same vector driven by RSV (Figure 1f) , as was found with CD34-enriched cells (data not shown). These data emphasize the need to optimize conditions for transduction in individual laboratories before initiating studies. We have previously shown by limiting cell dilution PCR that transfection frequencies range from 1-10% in PBMC, and 10 2 -10 4 copies of unintegrated plasmid DNA are initially transferred with this gene transfer procedure, most of which is not retained. By 10 days of cell culture, single copy levels are found which are largely integrated and stably maintained. 21 
Transfection of CD34
+ -enriched cells Enrichment of CD34 + cells was achieved by passing Ficoll-Hypaque-purified PBMCs obtained from cord blood samples twice over CD34 immunoaffinity columns. Following elution from the column, approximately 70-99% of the cells were CD34
+ by FACS analysis (Figure 2a) . The fold enrichment of CD34
+ cells was largely dependent on the initial frequency of these cells in the starting material but was in the order of 1500-to 6000-fold. Usually, between 150-500 × 10 6 PBMCs were obtained from a cord blood sample, of which CD34
+ cells represent 0.1-0.8% of the total cells. During the gene transfer protocol, an estimated 2-5% of the cells sustain physical damage from the transfection procedure, likely caused by the impact of beads on target cells and/or excessive drying that may occur immediately after transfection because of the small volumes. Thus, the procedure has a minimal effect on the overall viability of the population and subsequent colony-forming ability.
To determine the expression of cell surface glycoproteins following growth on stromal cells before transfection, expression of CD34, and a panel of lineage-specific antigens (lin = CD2, CD10, CD14, CD15, CD16, CD19 and glycophorin) were examined on multiple cord blood samples at various times after culture on stromal cells. These markers have been used previously to differentiate between committed and primitive progenitors cells. Cells examined on day 0 and day 1 showed the marker expression CD34
+ and were lineage-negative for many lineage markers (Figure 2b) . A small percentage of the cells were positive for the multilineage marker CD33 (data not shown), consistent with this population containing primitive progenitor cells at this time. Following culture on stromal cells for 3 days or longer, however, CD34 expression was reduced, and the expression of the macrophage-specific marker CD14 was seen ( Figure 2c ). No expression of the T cell marker CD3, NK marker CD16, and the B cell marker CD19, were seen at this or later time-points indicative that culture conditions give rise to cells predominantly of the myelomonocytic lineage.
To examine CAT expression in CD34-enriched cells carried on stromal cells over time, cord blood CD34 + cells were incubated for various times on mouse stromal cells, removed, and transduced by particle-mediated gene transfer. Following transfection, cells were incubated for an additional 2 days on stromal cells before analysis of CAT activity. Cells transduced on day 0 (ie immediately after isolation) and after 1 day on stromal cells showed consistently lower levels of CAT expression compared with cells which had been grown on stromal cells for 3 and 4 days before transfection (Figure 3 ). Although the levels of CAT activity were low on day 0 and day 1, the levels were high enough to ensure that gene transfer had occurred. Statistical analysis comparing levels of CAT activity between days 0 and days 3 and 4 gave P values To confirm stable granulocyte-macrophage progenitor gene expression in the CD34 + -enriched cell population, cells incubated for 0 or 4 days on stromal cells were transfected with the CMV-CAT expression plasmid. Following transfection, cells were plated in semi-solid methylcellulose for hematopoietic colony assays (CFU-GM) in the presence of G-418. Following the assay, the percentage of genetically modified CFU was estimated by comparing the number of CFUs obtained from cells transfected with a control vector which did not contain the neomycinresistance gene compared with cells transfected with CMV-CAT plasmids containing this resistance gene. CAT expression levels in cells transduced on day 0 or 4 and the percentage of CFU-GM following differentiation of these transfected cells in the presence of G-418 were determined ( Figure 4 ). Although some differences in CAT activity were seen between days 0 and 4, no difference was seen in their ability to generate G-418-resistant colonies in the CFU-GM assay. This observation would suggest that these progenitor cells obtained on day 0 can be reproducibly transfected, as well as those present on day 4. Even though expression levels as indicated by CAT activity are generally higher on day 4, some of this CAT activity may occur in more mature cells. Transfection efficiencies did not appear appreciably higher, but more cells receiving the recombinant gene on days 3 and 4 probably represented myelomonocytic cells which display higher CAT levels compared with the relatively quiescent cells transduced on day 0. The differences in CAT activity at these times could therefore be due either to greater efficacy of transfectability of these more differentiated GM-progenitor cells or their enhanced ability to express the recombinant reporter gene.
) were transduced with 800 ng CMV-CAT-neo expression vector (a-f), and CAT activity was measured 48 h after transfection. Various parameters were changed in the transfection conditions. (a) Diameter of the gold beads; (b) target distance, the distance between the stopping screen and the target cells; (c) pressure of helium gas used to propel the gold beads; (d) CD4 ϩ or CD4 Ϫ cells separated before bombardment; (e) Activation of PBMC, in which cells were transduced following 2 days of culture under the indicated activation conditions: no activation (none), with 100 IU IL-2/ml (IL-2) incubating on OKT-3-coated plates (␣CD3) incubating on OKT-3-coated plates and 100 IU IL-2/ml (␣CD3 and IL-2); (f) RSV-or CMV-CAT expression plasmids. CAT expression can only be compared within each set, as activity is not standardized for the same amount of protein and incubation time. Although the result of a single experiment was shown, the data represent the average of at least three independent gene transfer procedures. To control for variation in transfection efficiency between procedures, multiple biolistic transfections were performed under the indicated conditions, and the resulting transfected cells pooled before performing the CAT assay. The data are presented in the current form because CAT conversion levels can only be compared between samples in
Under these growth conditions, CFU-GM were the predominant colony type formed. In approximately 30% of experiments, 10-30% of the colonies formed from transfected cells in the absence of G-418 were BFU-E and less than 5% were CFU-GEMM. A relatively low concentration of G-418 used in the colony assay was chosen to balance the amount needed for adequate cell selection with that which would induce drug toxicity and give rise to breakthrough of cell growth in the control group. The toxicity of G-418 was evident in that no BFU-E or CFU-GEMM were observed in the presence of G-418, whereas in its absence these colonies were seen. Although the percentage of CFU in the control cells not containing the neomycin resistance gene was approximately 7% (Figure 4) , the difference between these values is significant and gives an indication of gene transfer and sustained expression of the marker gene. In cultures from genetically modified cells incubated in the presence of G-418, no BFU-E or CFU-GEMM were observed. The apparent absence of these specific colony types in the presence of G-418 is thought to be related to their relative sensitivity to G-418. Gene transfer in individual clones was also confirmed in comparable relative frequencies by PCR analysis (data not shown).
We have previously published a procedure for limiting cell dilution PCR analysis of transfected PBL, 26 which measures the percentage of cells that are transfected. We find that conditions optimized for PBL are also optimal for CD34 + cells, indicating that particle-mediated gene transfer is dependent on physical factors and not determined by cell type. In CD34
+ cord blood cells, we find by limiting cell dilution PCR that gene transfer frequencies are approximately 1-10% (Figure 5a ) and, by quantitative Southern blot analysis 24 h after gene transfer, 8.5-122 copies of plasmid DNA are detected per transfected cell (Figure 5b) . At 24 h, a large percentage of the unintegrated DNA was lost with a substantial percentage (approximately 80%) of plasmid DNA becoming integrated (Figure 5b ), consistent with results observed previously in PBL. 26 The rationale for the analysis of integration has been described previously. 21 Briefly, EcoRI cuts the plasmid at two sites, liberating an internal fragment, and PstI digests once, outside the region of the smaller EcoRI fragment (Figure 5b) . Thus, if the plasmids are unintegrated, digestion with both PstI and EcoRI would produce two bands, 1.4 and 2.8 kb, respectively, of equal intensity when probed with the internal EcoRI fragment since the plasmid is linearized by XmnI digestion before gene transfer. If the plasmid is integrated, the PstI digestion would not produce a discrete band as the plasmid would be randomly integrated into genomic DNA at the XmnI site and only EcoRI digestion, which gives rise to the internal plasmid EcoRI fragment, would produce a band. The 1.4 kb band, the EcoRI internal fragment, is clearly of higher intensity than the PstI band (Figure 5b ), indicating that integration has occurred in the majority of cells (approximately 80%). These data clearly suggest that stable integration and expression of a selectable gene has occurred with this technique.
Discussion
To control many diseases effectively, the sustained expression of recombinant genes in self-renewing hematopoietic stem cell populations is an important goal. Towards that end, we have begun to develop more efficient nonviral methods of transfection into hematopoietic progenitor cells. We have attempted to optimize gene transfer in hematopoietic progenitor cells using a nonviral gene delivery technique. This approach is based on previous studies of particle-mediated gene transfer for the transfection of primary T cells. This method has the potential to alter the biology of stem cells and can potentially be applied to the treatment of human disease.
Using particle-mediated gene transfer, we have previously shown that a plasmid DNA expressing Rev M10, a transdominant negative form of the HIV regulatory protein Rev, was stably transduced into primary T cells. 21 Effective gene transfer and expression of the introduced gene was observed as indicated by a significant reduction in viral replication in cells expressing Rev M10 following viral challenge with HIV. A human clinical study is aimed at addressing the potential of Rev M10 introduced by particle-mediated gene transfer to prolong the sur- vival of transduced CD4 positive T cells and suggests that cells transduced by this technique show increased survival compared with control cells. 26 No adverse effects of the treatment were documented in any of the patients.
Umbilical cord blood is an attractive source of HSC primarily due to its primitive origin in ontogeny, the ease of collection and availability which allows cryopreservation for subsequent use. Cord blood cells are also thought to contain higher numbers of long term-culture initiating cells (LT-CIC) than either mobilized stem cells 27 or bone marrow aspirates. 28 Following transfection of CD34 + -enriched cells with the CMV-CAT (neo containing) expression vector, sustained expression of the transgene in committed progenitor cells as assayed by CFU-GM was observed (Figure 4) . The efficiency of transfection in myeloid progenitors based on CFU-GM capacity following G-418 selection was approximately 30% for cells transfected on day 0 (which presumably at this time contain the highest levels of the most primitive cells) and approximately 18% for cells transduced after 4 days growth on stromal cells (mostly committed myleomonocytic cells). This frequency of transfection is similar to the 10-40% transduction frequency obtained previously in human HSC using MLVbased retroviral vectors. 2, 4, 7, 11, 15, [29] [30] [31] However, the possible advantage of the nonviral procedure is that the small proportion of CD34 + cells that may represent the most primitive progenitors may be more amenable to transfection by nonviral methods that do not require cells to be actively cycling. Although extrapolation from transient CAT expression levels to long-term expression and cell survival cannot be taken for granted, this study suggests levels of gene transfer as determined by reporter gene activity correlated approximately with the ability to generate CFU-GM. As overall CAT expression is a measure of activity in cells of many potential lineages, CFU-GM analysis alone will not give an exact estimation of the overall transfection efficiency in the cell population.
A possible improvement in this methodology would be attained by the enrichment of genetically modified cells via the utilization of vectors containing a reporter gene encoding an immunoselectable cell surface marker. This modification would enable transfected cells to be immunoselected and sorted by FACS before reconstitution into the appropriate model system for efficacy studies. Other investigators have used cell surface markers such as murine CD2, 32 Thy 1.2, 15 heat stable antigen, 33 and Lyt-2 34 to increase the enrichment of transfected cells and effectively separate non-transfected cells in the population. However, a limitation of this approach would be that the lower level of reporter expression in cells transduced on day 0 might limit the efficiency of selection. Studies involving these strategies are presently in progress, as well as the evaluation of the possible immunogenicity of cells expressing selectable cell surface markers. Although the present technology does not permit definitive assessment of whether particle-mediated gene transfer allows transfection of the multipotential self-renewing stem cells with recombinant genes, these findings demonstrate that early progenitor cells can be rapidly purified and transduced with recombinant genes with nonviral vectors that can be expressed as these cells progress to a variety of more differentiated hematopoietic lineages.
Materials and methods
Isolation of stem cells Human umbilical cord blood was obtained from the University of Michigan Hospital. The cord blood was diluted 1:3 with Dulbecco's-PBS (Gibco, Gaithersburg, MD, USA) and low density mononuclear cells were separated using Ficoll-Histopaque (Sigma, St Louis, MO, USA) as described previously.
21 CD34 + cells were purified by treating with anti-CD34 mab (QBEND-10; Miltenyi, Auburn, CA, USA) for 15 min at 4°C and microbeads coated with secondary antibody. The bound cells were removed using Miltenyi MiniMac System. This procedure was repeated to achieve greater purity.
Phenotype analysis
The purity of CD34-enriched cells were analyzed by FACScan using phycoerythrin-conjugated anti-CD34 antibody, and ranged from 60-99%. Monoclonal antibodies to markers of mature T lymphoid (CD2), B lymphoid (CD19), monocytic (CD14), granulocytic (CD15), NK (CD16) or erythroid (glycophorin A) were conjugated to FITC or isotype-matched antibody. The CD2, CD14, CD15, CD16, CD19, CD33, CD3, CD4, CD8 and relevant isotype-matched control anti-human antibodies were purchased from Caltag (S San Francisco, CA, USA). The CD34 (HPCA-2) antibody was obtained from Becton Dickinson (San Jose, CA, USA). Glycophorin A was purchased from Pharmingen (San Diego, CA, USA).
Culture conditions
The CD34 + -enriched cells were cultured on irradiated stromal cells 11 for the specified times at 37°C and 5% CO 2 in IMDM (Irvine Scientific, Santa Ana, CA, USA), supplemented with 20% FBS heat-inactivated (BioWhittaker, Walkersville, MD, USA), 1% deionized bovine serum albumin (Sigma), 2 mm l-glutamine, 50 U/ml penicillin, 50 g/ml streptomycin (Irvine Scientific), 10 mm hydrocortisone (Sigma) and 10 mm 2-mercaptoethanol supplemented with human recombinant IL-3 (5 ng/ml) (R& D Systems, Minneapolis, MN, USA), IL-6 (25 ng/ml) and human recombinant stem cell factor (50 ng/ml). The CD34 + -enriched cells were transduced using particlemediated gene transfer with various plasmids as described previously. 21 Chloramphenicol acetyltransferase (CAT) expression was measured 2 days after transfection and CFU assays were set up 1 day after transfection.
Stromal cells
Human bone marrow stromal cells were obtained by bone marrow aspiration as described previously. 11 The bone marrow aspirate (1 ml) was plated in 75 cm 2 flasks in a total of 15 ml of Dexter's original medium (DOM) consisting of IMDM supplemented with 15% FBS, 15% horse serum (heat inactivated), 2 mm glutamine, 50 U/ml penicillin, 50 g/ml streptomycin, 10 mm hydrocortisone, 100 mm 2 mecaptoethanol. After adhering cells overnight, unattached cells were washed off with HBSS (Hanks' balanced salt solution) (Irvine Scientific) and the adherent cells were propagated in DOM. Three cell passages were performed by trypsination and subculture until cells were used to support CD34 + cell cultures. 1 × 10 6 irradiated (20 Gy) stromal cells were plated into 25 cm 2 flasks in DOM.
Plasmids and CAT assay pCMV-CAT plasmid was constructed as described previously. 23 The CAT assay was performed as described. 35 Briefly, cells (1-10 × 10 6 ) were washed twice in PBS, resuspended in 0.25 m Tris pH 7.8, and disrupted by freeze/thawing in dry ice and ethanol three times. The extract (20-40 g protein) was incubated with 50 mm Tris pH 7.8, 14 C-labeled chloramphenicol and acetyl coenzyme A for 1-4 h at 37°C. Amounts were standardized so that equal protein concentrations (which corresponded to a similar number of transfected cells) were used in each experiment. The acetylated forms of chlorophenicol were extracted with ethyl acetate and the product applied to a thin-layer chromatography (TLC) plate. Following TLC with chloroform and methanol (95:5), the plate was dried at room temperature and the radioactivity measured using a Beta counter. The acetylated product was divided into acetylated and nonacetylated and multiplied by 100 to calculate the % converted.
Transfection procedure CD34
+ -enriched cells were transduced with plasmids by particle-mediated gene transfer as described previously. 21 Briefly, plasmid DNA was precipitated onto gold beads (1.6 m in diameter) by treatment with CaCl 2 and spermidine. Following washing of the DNA-coated beads with ethanol, the beads were delivered into cells using a Biolistic PDS-1000/He System (Bio-Rad, Hercules, CA, USA).
CFU assay
The assay was performed as described previously. 36 The CD34 + -enriched cells transfected on specified days were plated at a cell concentration of either 2 × 10 3 or 4 × 10 3 in methycellulose supplemented with human recombinant IL-3 (10 ng/ml), SCF (50 ng/ml), IL-6 (30 ng/ml), GM-CSF (50 ng/ml) and erythropoietin (2 U/ml) with or without neomycin (1 mg/ml). The colonies were counted 14 days later for GM, BFU-E or mixed colonies. GM colonies were observed under both conditions, but BFU-E and mixed colonies (CFU-GEMM) were only seen on plates without neomycin. The percentage of CFU after gene transfer was expressed as the number of colonies formed (CFU-GM + BFU-E + CFU-GEMM) in the presence of G418 divided by the total number of colonies in the absence of G418 multiplied by 100, which reflects the percentage of colonies which display neomycin resistance. After growth for 14 days, colonies containing more than 50 cells were counted.
